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Thrombotic disorders may be inherited, as 
discussed in part 1 (previous issue),[1] or 
acquired. They are the subject of discussion 
in this issue, the second of a 2-part series 
in CME. 
The process of coagulation involves 
activation, adhesion and aggregation of 
platelets to damaged endothelium, followed 
by deposition and maturation of fibrin, and 
begins almost immediately after injury to 
the endothelial lining of the blood vessel. 
Exposure of blood to the subendothelial 
area initiates two processes, viz. changes in 
platelets, and the exposure of subendothelial 
tissue factor (TF) to plasma factor VII 
(FVII). Platelets immediately form a plug 
at the site of injury, which is referred 
to as primary haemostasis. Secondary 
haemostasis occurs simultaneously where 
additional coagulation factors beyond FVII 
respond in a cascade to form fibrin strands, 
which confer stability to the platelet plug 
(Fig. 1).[2]
The TF-FVIIa complex is a crucial trigger 
for haemostatic responses in vivo, and exces-
sive initiation of coagulation through this 
pathway can lead to thrombosis or consump -
tive coagulopathy. Increased TF-FVIIa com-
plex formation can result from loss of vascu-
lar wall integrity and increased TF expression. 
For example, atherosclerotic plaques contain 
significant levels of TF, generally associated 
with monocytes/foam cells and smooth-
muscle cells.[2] TF expression can also be 
increased with malignancy, potentially leading 
to cancer-associated thrombosis.[3] During 
sepsis, TF is expressed on monocytes, but is 
also expressed by endothelial cells in some 
areas, such as the splenic microvasculature.[4]
Causes of acquired thrombophilia are listed 
in Table 1.
A more detailed discussion is given 
below regarding acquired risk factors 
for thrombosis, as well as information 
pertaining to clinical entities characterised 
by a marked predilection to thrombosis (i.e. 
the antiphospholipid syndrome, hepa rin- 
induced thrombocytopenia and paroxysmal 
nocturnal haemoglobinuria). Thrombophilia 
associated with specific clinical scenarios 
mainly affecting the arterial circulation 
and microvasculature (e.g. myocardial 
infarction, diabetes, hypertension, thrombotic 
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Fig. 1. Coagulation cascade. Dotted arrows indicate actions of natural anticoagulants and fibrinolytic 
factors. (V, VIII, IX, X, XI, XIII = procoagulant factors; suffix a = activated factor; AT = antithrombin; 
TF = tissue factor; I = fibrinogen; II = thrombin; Plg = plasminogen; PL = phospholipid (on platelet 
membrane); TFPI = tissue factor pathway inhibitor; tPA = tissue plasminogen activator; PT = pro­
thrombin; APC = activated protein C; PS = protein S; TM = thrombomodulin; α2AP = α2-antiplasmin; 
PC = protein C.)
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thrombocytopenic purpura (TTP)) are influenced by a multitude 
of factors and varied aetiologies. Such scenarios merit discussion 
on discipline-specific platforms and therefore do not fall within the 
scope of this CME. The scope of this discussion is limited to clinical 
entities associated with a marked increase in the risk of thrombosis. 
We conclude with a guide to the diagnosis and further investigation 
of suspected thromboembolic disease.
Acquired risk factors for thrombosis
Mycobacterium tuberculosis infection
The risk of venous thromboembolism (VTE) is 1.5 times higher 
in patients with Mycobacterium tuberculosis (TB) infection than in 
uninfected individuals and relates to immobilisation, increase in 
procoagulant acute-phase reactants such as fibrinogen, decrease in 
the natural anticoagulants including protein C (PC) and protein S 
(PS), and mechanical compression of veins from enlarged lymph 
nodes.[5] Active TB infection is also frequently linked to underlying 
infection with HIV, which further increases the risk of VTE.[6] 
Concomitant HIV infection and VTE during TB treatment can 
result in clinically significant drug-drug interactions, as warfarin 
is metabolised by the cytochrome P450 (CYP450) pathway in the 
liver. Therapeutic agents that induce this pathway (e.g. rifampicin 
and nevirapine) or inhibit it (e.g. isoniazid and efavirenz), may 
result in under- or over-anticoagulation, necessitating more intense 
monitoring and management of anticoagulation therapy.
HIV infection
The incidence of arterial and venous thrombosis in HIV-infected 
patients is increased compared with healthy controls. The patho-
genesis of the hypercoagulability in people infected with HIV is 
multifactorial and relates to an increase in procoagulant acute-phase 
reactants (Von Willebrand factor, fibrinogen and FVIII), a decrease 
in the level of natural anticoagulants (PC and PS), production 
of lupus anticoagulant antibodies due to immune dysregulation 
and endothelial dysfunction. Concomitant disease processes in 
HIV-infected patients, including secondary malignancies, additional 
infections, concurrent immobilisation and drugs, can also contribute 
to the increased thrombotic risk that has been recognised in VTE 
treatment and prophylaxis guidelines.[7-9]
Renal disease
Chronic kidney disease (CKD) is an established risk factor for arterial 
and venous thrombosis. The latter occurs 5.5 times more frequently in 
patients with CKD than in people with normal renal function.[10] The 
hypercoagulable state in patients with CKD relates to procoagulant 
factors (antiphospholipid antibodies, artificial shunts and indwelling 
catheters), concomitant use of erythropoietin-stimulating agents, 
decline in fibrinolytic activity and decreased natural anticoagulant 
levels. Anticoagulation therapy in patients with renal dysfunction can 
be challenging owing to altered drug pharmacokinetics, necessitating 
dose adjustment and more intense monitoring.[10,11]
Inflammatory bowel disease 
Patients with inflammatory bowel disease (IBD), the major forms 
of which are ulcerative colitis (UC) and Crohn’s disease (CD), have 
a 3-fold increased risk of developing venous and, to a lesser extent, 
arterial thrombosis. The hypercoagulability in patients with IBD is 
multifactorial and not completely understood, but relates to chronic 
inflammation with increases in acute-phase reactants and cytokines, 
hospitalisation, surgery and indwelling catheters. VTE episodes 
usually correlate with disease activity, although these may occur 
during periods of remission. There is evidence that patients with IBD 
experience the first episode of VTE at a younger age than the general 
population, with an increased risk of recurrence, and that UC and CD 
pose an equal thrombotic risk.[12,13]
Pregnancy/oral contraceptive use
Among women, additional risk factors for VTE include combined 
oral contraceptives (OCs), hormone replacement therapy, pregnancy 
and the postpartum period. 
Oestrogen use increases the risk of VTE as a class effect, which is dose 
dependent. The risk of VTE depends on the route of administration. 
There is lower associated risk with transdermal and intrauterine 
hormonal therapy, as well as with progesterone-only OC use.[14]
The risk of VTE is increased 5 - 10-fold in pregnancy. The 
hypercoagulability of pregnancy persists for several weeks after 
delivery, where the greatest risk for VTE is in the early postpartum 
period. The recent decline in maternal deaths from VTE can be 
attributed to the use of thromboprophylaxis in high-risk women.[15,16]
VTE risk assessment is recommended early during pregnancy 
and in the postpartum period. Risk factors include previous VTE, 
family history of VTE, hereditary thrombophilia, antiphospholipid 
syndrome (APS), medical comorbidities, significant pregnancy 
compli ca tions, caesarean delivery, prolonged antepartum immobi -
li sation and clinical risk factors, such as increased body mass index 
(BMI), age >35 years and parity ≥3. High-risk patients should be 
managed in conjunction with a haematologist and, in the case of APS, 
a rheumatologist. Antepartum and postpartum thromboprophylaxis 
with low-molecular-weight heparin (LMWH) and low-dose aspirin is 
recommended in women with APS and previous VTE. Higher doses 
of LMWH may be required.[16]
The ideal anticoagulant in pregnancy does not cross the placenta 
and can be easily reversed. The oral direct thrombin and FXa 
inhibitors should not be used in pregnancy, as the molecules are 
small and cross the placenta. Warfarin is associated with a teratogenic 
effect, especially between 6 and 12 weeks’ gestation. Furthermore, 
there is an increased risk of miscarriage, prematurity and fetal 
bleeding (including intracranial haemorrhage resulting in brain 
damage) at any time during pregnancy. LMWH is the preferred 
anticoagulant. Antepartum prophylaxis should be initiated early in 
Table 1. Precipitating factors/conditions associated with 
thrombosis
Antiphospholipid antibodies
Atrial fibrillation/congestive cardiac failure




Oral contraceptive use/pregnancy/oestrogen therapy
Diabetes mellitus/obesity
Hyperviscosity
Chronic haemolysis, e.g. SCD, PNH




TB = tuberculosis; SCD = sickle cell disease; PNH = paroxysmal nocturnal haemo globinuria; 
HIT = heparin-induced thrombocytopenia; TTP = thrombotic thrombocytopenic 
purpura. 
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pregnancy. Postpartum thromboprophylaxis should be continued for 
6 weeks in high-risk women, for 10 days in intermediate-risk women 
and at least until discharge from hospital in low-risk women. There is 
an increased dose requirement for LMWH during pregnancy because 
of increased volume of distribution and renal clearance. Regular anti-Xa 
monitoring is therefore recommended. 
Obesity
Obesity is defined as a BMI ≥30 kg/m2. Owing to its increasing 
prevalence, obesity has emerged as an important risk factor for VTE 
in addition to myocardial infarction and stroke in high-income 
countries. In South Africa (SA), a resource-limited country, there is 
a bimodal distribution, with a rise in obesity, particularly in urban 
settings. Central obesity is characterised by chronic inflammation 
and impaired fibrinolysis, which are the two major pathways that 
contribute to VTE risk.[17] 
As obesity is considered a moderate risk factor for VTE in high-
risk circumstances, such as hospitalised medical patients, surgery and 
immobilisation, thromboprophylaxis should be considered. Higher 
doses of LMWH are often required for the prevention of VTE in 
obese patients.[18] Laboratory monitoring of LMWH therapy in obese 
patients using anti-Xa levels is indicated. There are limited clinical 
data available on the use of direct oral anticoagulants (DOACs), 
such as dabigatran, rivaroxaban and apixaban, for patients with a 
BMI ≥40 kg/m2. DOAC activity levels should be monitored in these 
patients using a drug-specific peak level.[19]
Cancer
The risk of VTE is significantly increased among patients with 
cancer, with an estimated relative risk 4 - 7-fold above that of the 
background population.[20] The basis for malignancy-associated 
VTE include factors related to the cancer itself (such as expression 
of procoagulant molecules, particularly TF, by the tumour cells), 
chemotherapy-related endothelial injury and/or increased frequency 
of other risks for VTE (e.g. major surgery, immobilisation, vascular 
obstruction by tumour masses or indwelling venous catheters).[21] 
VTE rates are particularly high in certain types of cancer (such as 
haematological neoplasms, and tumours of the stomach, pancreas, 
brain, lung and breast),[21,22] in advanced-stage disease and when 
therapeutic agents with increased thrombogenic potential are used, 
such as platinum-based chemotherapy agents, immunomodulatory 
drugs (e.g. thalidamide, tamoxifen) and haemopoietic-stimulating 
agents (e.g. erythropoietin).[21,22] 
Despite the increased risk of VTE in association with cancer, 
routine primary prophylaxis among ambulatory individuals with a 
malignancy is not advocated, as the rate of bleeding complications 
is also elevated with LMWH-based VTE prophylaxis.[21,22] However, 
thromboprophylaxis is recommended for hospital inpatients, 
particularly following major surgery, such as abdomenopelvic surgery, 
which necessitates prophylaxis with LMWH for 30 days.[21] Among 
patients with confirmed thrombosis, therapeutic doses of LMWH 
have shown superior efficacy compared with oral vitamin K antagonists, 
possibly due to difficulties in achieving predictable anticoagulation 
in patients with cancer owing to numerous drug-drug interactions, 
poor diet/vomiting (which can affect vitamin K bio-availability) 
or associated liver/renal impairment.[21] Early indications suggest 
that the DOACs, rivaroxaban, apixaban and edoxaban (of which 
only rivaroxaban is currently available in SA), may be acceptable 
alternatives for the management of VTE, but caution is warranted if 
potent inducers or inhibitors of CYP450 are used concomitantly.[21,23] 
Furthermore, these agents have been associated with an increased 
risk of bleeding in patients with gastrointestinal cancers, and should 
be used with caution in this group.[23] This has led the Scientific and 
Standardization Committee on Haemostasis and Malignancy of 
the International Society of Thrombosis and Hemostasis (ISTH) to 
recommend the use of DOACs only in patients with a low bleeding risk 
who do not use agents likely to cause drug-drug inter actions.[24] Cancer-
associated thrombosis should be treated for at least 3 - 6 months, and 
as the risk of recurrence is increased, ongoing anticoagulation should 
be considered while the patient has active cancer.[23] 
Among otherwise apparently well patients who present with 
unprovoked thrombosis, a small proportion can be demonstrated 
to be harbouring occult malignancies. Limited cancer screening 
is therefore recommended by the ISTH in this group of patients, 
including a clinical evaluation, chest radiograph, full blood 
count, liver function testing, serum calcium, urinalysis and age-
appropriate screening tests (e.g. prostate-specific antigen level, 
mammography).[25] Patients who experience recurrent VTE while 
on anticoagulant therapy or bilateral deep-vein thrombosis are at 
particularly high risk of occult cancer, and may benefit from a more 
extensive work-up in the case of underlying malignancy.[20] 
Sickle cell disease
VTE is a common comorbid condition found in sickle cell disease 
(SCD) and is associated with increased mortality. 
The incidence of thrombotic stroke and pulmonary embolism 
is higher than in persons without SCD.[26,27] SCD is also a risk 
factor for pregnancy-related VTE (odds ratio (OR) 20.3).[28] As the 
pathogenesis of vaso-occlusion is multifactorial, the precise role 
of hypercoagulability is not certain. The preponderance of evidence 
demonstrates increased platelet and coagulation activation. 
Prothrombin fragment 1.2, a marker of thrombin generation, is 
elevated in SCD. Phosphatidyl serine exposure on the surface of the 
red cell membrane is thought to serve as a trigger, with contributing 
factors, such as functional asplenia and nitric oxide depletion due to 
chronic haemolysis.[29] 
Prophylactic anticoagulation is recommended during potentially 
triggering events such as perioperative periods and indwelling venous 
catheters. Meaningful data on the long-term use of anticoagulants 
or antiplatelet agents are lacking owing to small and/or poorly 
controlled studies. 
Clinical entities characterised by a 
thrombotic tendency
The antiphospholipid syndrome 
APS is associated with a predilection to thrombosis and recurrent 
morbidity related to pregnancy. Thrombosis can affect any vessel 
(arterial, venous or the microvasculature), and recurs often. The 
pathogenesis of thrombotic APS is not well understood, but the 
binding of autoantibodies directed against various phospholipids 
or phospholipid-binding proteins (including cardiolipin and beta-2 
glycoprotein I) results in: (i) upregulated monocyte and endothelial 
cell TF expression; (ii) platelet activation; and (iii) disruption of 
natural anticoagulant mechanisms (such as the activated PC pathway 
and the annexin V shield (which blocks access of coagulation 
factors to procoagulant phospholipid surfaces).[30] The most common 
thrombotic manifestations include cerebrovascular accidents, lower-
limb deep-vein thrombosis and pulmonary embolism.[3] APS should 
be suspected if:
• thrombosis occurs in a young patient, at an unusual site or recurs[31]
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• other clinical features associated with APS are present, including 
underlying systemic lupus erythematosus, mild thrombocytopenia, 
autoimmune haemolysis, livedo reticularis, cardiac valve 
thickening or vegetations, thrombotic microangiopathy, recurrent 
miscarriages, nephropathy, neurological abnormalities or unex-
plained prolongation of the activated partial thromboplastin time 
(aPTT).[31]
The diagnosis is based on the revised Sapporo criteria, which require 
demonstration of ≥1 laboratory criteria with ≥1 clinical manifestations 
(Table 2).[32] The laboratory findings (i.e. anticardiolipin antibodies, 
anti-beta-2 glycoprotein antibodies or a lupus anticoagulant) are 
somewhat nonspecific, and can occur transiently after a viral infection 
or secondary to underlying autoimmune pathology, malignancy or 
drug exposure. Persistence of these abnormalities must therefore be 
demonstrated for >12 weeks with appropriate clinical manifestations 
before a diagnosis of APS can be made. 
Management of thrombotic APS entails lifelong anticoagulation 
with a vitamin K antagonist (such as warfarin and a target 
international normalised ratio (INR) of 2 - 3), with optimisation 
of other risk factors for thrombosis (e.g. hypertension, hyper-
cholesterolaemia). Concomitant use of aspirin is advocated for 
arterial thrombosis in patients with significant risk factors for 
cardiovascular disease. In the event of recurrent thrombosis despite 
adequate anticoagulation (a well-described complication), options 
include the addition of aspirin, use of high-dose vitamin K antagonist 
therapy (target INR 3 - 4) and/or an alternative anticoagulant 
(particularly LMWH). Currently, DOACs are not advocated for the 
management of APS, as their efficacy and safety are not proven.[31]
Heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is an immunological 
compli cation of heparin therapy that is associated with a decrease 
in the platelet count (usually resulting in thrombocytopenia) and an 
increase in the risk of thrombosis (both venous and arterial).[33,34] It 
typically develops 5 - 10 days after the commencement of heparin 
therapy, except in patients with a history of recent heparin exposure, 
in whom the clinical features may manifest more rapidly. It is caused 
by the production of antibodies directed against a complex of heparin 
and platelet FIV (PF4), which is an endogenous platelet protein 
released from the alpha granules of platelets on platelet activation.[33,34] 
When bound to heparin-PF4 complexes, these antibodies cross-link 
FcƔRIIa receptors on platelets and monocytes, which generates 
a prothrombotic state by triggering platelet activation and TF 
expression on the surface of monocytes.[34] 
These antibodies occur fairly commonly in patients exposed to 
heparin, but HIT occurs in only 0.2 - 3.0% of such patients.[34] Factors 
associated with a high risk of HIT include a history of recent 
major surgery, unfractionated heparin (UFH) exposure and use of 
therapeutic doses of LMWH.[34] Notably, the risk of HIT is significantly 
lower with prophylactic doses of LMWH.[33,34] Diagnosis is primarily 
based on clinical suspicion, with the presence of thrombocytopenia 
or thrombosis at the appropriate time interval following heparin 
exposure without an alternative cause (assessed in the 4T score) 
(Table 3). HIT can be excluded if the 4T score is low (<4), but requires 
laboratory confirmation when the score is intermediate or high.[33,34] 
Laboratory tests available in SA include functional tests that detect 
platelet activation upon heparin exposure, as well as immunoassays 
that demonstrate antiheparin/PF4 antibodies. The immunoassays 
have superior sensitivity, but poorer specificity; therefore, while a 
negative result excludes a diagnosis of HIT, a positive result is only 
confirmatory when the 4T score is high.[34] In contrast, the sensitivity of 
the functional assay is lower, but its specificity is higher, and a positive 
functional test result therefore confirms a diagnosis of HIT, even in 
patients with an intermediate 4T score.[34] Knowledge regarding the type 
of assay performed is important; therefore, consultation with regional 
laboratory services is necessary. 
Management of HIT entails immediate cessation of heparin therapy 
and commencement of an agent that does not cross-react with the 
antiheparin/PF4 antibodies. Importantly, the results of laboratory 
assays should not be awaited before initiating the alternative 
anticoagulant, as the risk of thrombosis is very high (~50%),[33] and 
the test results are often not available for a few days. Agents that can 
be employed include parenteral inhibitors of thrombin (argatroban), 
FXa (fondaparinux) or the DOACs (dabigatran or rivaroxiban).[35] 
LMWH should be avoided. Warfarin is contraindicated, as warfarin-
related PC deficiency may cause significant extension of the 
thrombus, with a risk of venous gangrene.[33,34] In the absence 
Table 2. Revised Sapporo classification criteria for the diagnosis of antiphospholipid syndrome[32]
Clinical criteria
Objectively confirmed arterial, venous or small-vessel thrombosis in any organ 
Pregnancy morbidity 
• ≥1 unexplained death/s of a morphologically normal fetus at or beyond the 10th week of gestation
• ≥1 premature birth/s of a morphologically normal neonate before the 34th week of gestation due to eclampsia, severe pre-eclampsia or 
placental insufficiency
• ≥3 unexplained, consecutive spontaneous miscarriages before the 10th week of gestation (without maternal anatomical or paternal and 
maternal chromosomal abnormalities)
Laboratory criteria
LA on ≥2 occasions at least 12 weeks apart (detected by prolongation of a phospholipid-dependent clotting time, e.g. DRVVT, lupus-sensitive 
aPTT)
ACL antibody (IgG and/or IgM) measured by an ELISA-based immunological assay, present in medium- or high-titre (i.e. ≥40 GPL or MPL), 
on ≥2 occasions, at least 12 weeks apart 
Anti-β2-glycoprotein I (IgG and/or IgM) measured by an ELISA-based immunological assay, present in medium- or high-titre (i.e. ≥99th percen -
tile), on ≥2 occasions, at least 12 weeks apart
Patients with LA positivity are at greater risk of clinical events, particularly those with triple positivity for LA, ACL and anti-β2-glyco protein I
LA = lupus anticoagulant; DRVVT = dilute Russell viper venom time; aPTT = activated partial thromboplastin time; ACL = anticardiolipin; ELISA = enzyme-linked immunosorbent assay; 
GPL = IgG phospholipid; MPL = IgM phospholipid.
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of thrombosis, alternative anticoagulation 
treatment should be maintained for 4 weeks. 
If thrombosis is present, warfarin should 
be commenced once the platelet count has 
normalised (>150 × 109/L on ≥2 occa sions), 
and continued for 3 months.[34] 
Paroxysmal nocturnal 
haemoglobinuria 
Paroxysmal nocturnal haemoglobinuria 
(PNH) is a rare clonal disorder that is caused 
by an acquired mutation of the PIG­A gene, 
which encodes an anchor molecule (glyco-
sylphosphatidylinositol (GPI)) required for 
affixing a number of proteins on cell surfaces 
(including the complement-inactivating pro-
teins CD55 and CD59).[36] Cells with GPI 
deficiency are thus vulnerable to comple-
ment activation on their surfaces, which 
can cause cell lysis (in the case of red cells), 
cellular activation (in the case of platelets) 
and indirectly, endothelial dysfunction.[36,37] 
This accounts for the clinical manifestations 
of PNH, which include episodic haemo-
globinuria (due to intravascular haemolysis) 
and a predilection to thrombosis. PNH-
positive clones may also be seen in patients 
with underlying haematological disorders 
(particularly aplastic anaemia), although 
typical clinical manifestations of PNH are 
unusual in this setting. PNH should be sus-
pected in patients with thrombosis, who also 
have cytopenias, iron deficiency (as a conse-
quence of long-standing haemo globinuria), 
evidence of intravascular haemolysis or 
when thrombosis is detected at unusual 
sites (particularly intra-abdo minal or cere-
bral veins).[37] Diagnosis is made on flow 
cytometry, which is used to detect cell popu-
lations that do not express GPI-linked surface 
antigens.[36] PNH-associated thrombosis can 
be very difficult to manage; these patients 
should be referred to specialist haematology 
centres. 
Diagnostic considerations
The algorithm in Fig. 2 outlines a diagnostic 
approach for suspected thrombo embolic dis-
ease.[38] Wells’ scores for clinical assessment of 
deep-vein thrombosis and pulmonary embo-
lism appear in Tables 4 and 5, respectively.
Thrombophilia testing 
FV Leiden (which does not occur among black 
population affinity groups) and prothrombin 
gene (20210A) mutations together with 
antiphospholipid antibodies constitute the 
most prevalent thrombo philias. Deficiencies 
of the natural anticoagulants (PC, PS and 
antithrombin) and elevated homocysteine 
levels tend to be of low yield, and testing for 
these should generally be limited to patients 
with particularly high-risk and unique 
presentations.
Thrombophilia testing need not be done 
in patients with a clear provoking event, 
such as recent major orthopaedic surgery in 
the absence of other factors suspicious for 
thrombophilia, or in those with underlying 
malignancy, as results are unlikely to alter 
the treatment plan.
Samples for FV Leiden and pro thrombin 
gene (20210A) mutations, as well as anti-
Table 3. 4T scoring system* for the diagnosis of heparin-induced thrombocytopenia
+2 +1 0
Thrombocytopenia Platelet count fall >50% and 
platelet nadir ≥20
Platelet count fall 30 - 50% or 
platelet nadir 10 - 19
Platelet count fall <30% or 
platelet nadir <10
Timing Definite onset between days 5 and 
10 or platelet count fall ≤1 day 
if heparin exposure in the past 
30 days
Probable onset between
days 5 and 10, but not clear; 
onset after day 10 or platelet 
count fall ≤1 day if heparin 
exposure in the past 30 - 100 days 
Platelet count fall <4 days 
without recent exposure
Thrombosis New thrombosis or skin necrosis/
acute systemic reaction after 
intravenous heparin bolus




Other causes for thrombocytopenia None apparent Possible Definite
*<4 = low risk; 4 - 5 = intermediate risk; 6 - 8 = high risk. Heparin was started on day 0.
Symptoms of DVT: unilateral leg swelling, redness, pain or 
discomfort, warmth and tenderness to touch 
Symptoms of PE: dyspnoea, chest pain or tightness, 
haemoptysis, syncope or collapse, tachycardia and/
or hypotension (shock) 
Apply clinical decision rule 
• suspected DVT: Wells' DVT score (Table 4) 
• suspected PE: Wells' PE score (Table 5) 
Negative       Positive Perform compression ultrasonography 
(Doppler) for leg DVT or computed 
tomography pulmonary angiography for PE 
Negative       Positive
Perform D-dimer blood test
DVT or PE excluded DVT or PE conrmed
VTE unlikely                                   VTE likely
Fig. 2. Diagnostic approach for patients with suspected venous thromboembolism. (VTE = venous 
thromboembolism; DVT = deep­vein thrombosis; PE = pulmonary embolism.)
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phospholipid antibodies (excluding functional lupus anticoagulant), 
can be collected in the acute phase of thrombosis, as these results 
are not affected by acute thrombosis or anticoagulants. Functional 
lupus anticoagulant testing, as well as testing for PC and PS and 
antithrombin deficiencies, should preferably be delayed until completion 
of anticoagulation therapy. However, these can be collected in the acute 
phase prior to initiation of therapy in those patients who might require 
lifelong anticoagulation.
Conclusions
The aetiology and pathogenesis of acquired thromboses are fairly 
diverse and depend to a large extent on the primary pathology and 
associated compounding factors. 
An accurate history (with knowledge of pre-existing conditions), 
physical examination and appropriate investigations are imperative 
for proper diagnosis and management of acquired thrombophilia. 
Declaration. None.
Acknowledgements. None.
Author contributions. NAA: concept, design and content; JV: design and 
content; SL: content; ES: content; and BJ: content.
Funding. None.
Conflicts of interest. None.
1. Alli NA, Vaughan J, Louw S, Schapkaitz E, Jacobson B. Thrombotic disorders (part 1). S Afr Med J 
2020;110(2):83-87. https://doi.org/10.7196/SAMJ.2020.v110i2.14594
2. Gale AJ. Current understanding of hemostasis. Toxicol Pathol 2011;39(1):273-280. https://doi.
org/10.1177/0192623310389474
3. Sud R, Khorana AA. Cancer-associated thrombosis: Risk factors, candidate biomarkers and a risk 
model. Thromb Res 2009;123(suppl 4):S18-S21. https://doi.org/10.1016/S0049-3848(09)70137-9 
4. Bode M, Mackman N. Regulation of tissue factor gene expression in monocytes and endothelial cells: 
Thromboxane A2 as a new player. Vascul Pharmacol 2014;62(2):57-62. https://doi.org/10.1016/j.
vph.2014.05.005
5. Dentan C, Epaulard O, Seynaeve D, Genty C, Bosson JL. Active tuberculosis and venous 
thromboembolism: Association according to international classification of diseases. Clin Infect Dis 
2014;58(4):495-501. https://doi.org/10.1093/cid/cit780
6. Hodkinson KE, Mahlangu JN. Deep-vein thrombosis in the era of high HIV and tuberculosis 
prevalence: A prospective review of its diagnosis and treatment in a quaternary centre. S Afr Med J 
2017;107(10):859-863. https://doi.org/10.7196/SAMJ.2017.v107i10.12443
7. Jong E, Louw S, Meijers JC, et al. The hemostatic balance in HIV-infected patients with and without 
antiretroviral therapy: Partial restoration with antiretroviral therapy. AIDS Patient Care STDS 
2009;23(12):1001-1007. https://doi.org/10.1089/apc.2009.0173
8. Mayne ES, Louw S. Good fences make good neighbors: Human immunodeficiency virus and vascular 
disease. Open Forum Infect Dis 2019;6(11):ofz303. https://doi.org/10.1093/ofid/ofz303
9. Jacobson BF, Louw S, Buller H, et al. Venous thromboembolism: Prophylactic and therapeutic practice 
guideline. S Afr Med J 2013;103(4):260-267. https://doi.org/10.7196/samj.6706
10. Dager WE, Tsu LV, Pon TK. Considerations for systemic anticoagulation in ESRD. Semin Dial 
2015;28(4):354-362. https://doi.org/10.1111/sdi.12376
11. Lutz J, Menke J, Sollinger D, Schinzel H, Thurmel K. Haemostasis in chronic kidney disease. Nephrol 
Dial Transplant 2014;29(1):29-40. https://doi.org/10.1093/ndt/gft209
12. Giannotta M, Tapete G, Emmi G, Silvestri E, Milla M. Thrombosis in inflammatory bowel diseases: 
What’s the link? Thromb J 2015;13:14. https://doi.org/10.1186/s12959-015-0044-2
13. Zezos P, Kouklakis G, Saibil F. Inflammatory bowel disease and thromboembolism. World J Gastroenterol 
2014;20(38):13863-13878. https://doi.org/10.3748/wjg.v20.i38.13863
14. Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk 
of venous thrombosis: Systematic review and network meta-analysis. BMJ 2013;347:f5298. https://doi.
org/10.1136/bmj.f5298 
15. Wilkinson H, Trustees, Medical Advisers. Saving mothers’ lives. Reviewing maternal deaths to 
make motherhood safer: 2006 - 2008. Br J Obstet Gynaecol 2011;118(11):1402-1404. https://doi.
org/10.1111/j.1471-0528.2011.03097.x
16. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: 
Antithrombotic therapy and prevention of thrombosis. Chest 2012;141(2 Suppl):e691S-e736S. https://
doi.org/10.1378/chest.11-2300 
17. Morange PE, Alessi MC. Thrombosis in central obesity and metabolic syndrome: Mechanisms and 
epidemiology. Thromb Haemost 2013;110(4):669-680. https://doi.org/10.1160/TH13-01-0075
18. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current 
doses may be inadequate in obese patients. Br J Surg 2003;90(9):1165-1166.
19. Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese 
patients: Guidance from the SSC of the ISTH. J Thromb Haemost 2016;14(6):1308-1313. https://doi.
org/10.1111/jth.13323
20. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous 
thrombosis. Blood 2013;122(10):1712-1723. https://doi.org/10.1182/blood-2013-04-460121 
21. Fernandes CJ, Morinaga LTK, Alves JL, jun., et al. Cancer-associated thrombosis: The when, how and 
why. Eur Respir Rev 2019;28(151):pii180119. https://doi.org/10.1183/16000617.0119-2018
22. Streiff MB. Thrombosis in the setting of cancer. Hematol Am Soc Hematol Educ Program 
2016;2016(1):196-205. https://doi.org/10.1182/asheducation-2016.1.196
23. Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism. Blood 
2019;133(4):291-298. https://doi.org/10.1182/blood-2018-08-835595 
24. Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer 
associated venous thromboembolism: Guidance from the SSC of the ISTH. J Thromb Haemost 
2018;16(9):1891-1894. https://doi.org/10.1111/jth.14219
25. Delluc A, Antic D, Lecumberri R, Ay C, Meyer G, Carrier M. Occult cancer screening in patients with 
venous thromboembolism: Guidance from the SSC of the ISTH. J Thromb Haemost 2017;15(10):2076-2079. 
https://doi.org/10.1111/jth.13791
26. Lijfering WM, Brouwer JL, Veeger NJ, et al. Selective testing for thrombophilia in patients with first 
venous thrombosis: Results from a retrospective family cohort study on absolute thrombotic risk for 
currently known thrombophilic defects in 2 479 relatives. Blood 2009;113(21):5314-5322. https://doi.
org/10.1182/blood-2008-10-184879 
27. Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with 
venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis 2009;28(4):401-409. 
https://doi.org/10.1007/s11239-009-0378-3 
28. Noubiap JJ, Temgoua MN, Tankeu R. Sickle cell disease, sickle trait and the risk for venous thromboembolism: 
A systematic review and meta-analysis. Thromb J 2018;16:27. https://doi.org/10.1186/s12959-018-0179-z 
29. De  Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell desease. Semin Thromb 
Hemost 2011;37(3):226-236. https://doi.org/10.1055/s-0031-1273087
30. Linnemann B. Antiphospholipid syndrome – an update. Vasa 2018;47(6):451-464. https://doi.
org/10.1024/0301-1526/a000723
31. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 
2018;379(13):1290. https://doi.org/10.1056/NEJMc1808253
Table 4. Wells’ score* for deep-vein thrombosis 
Criteria Points
Active cancer (patient either received treatment during the previous 6 months or currently receiving palliative treatment) +1
Paralysis, paresis or recent cast immobilisation of the lower extremities +1
Recently bedridden for ≥3 days, or major surgery within the previous 12 weeks, requiring general or regional anaesthesia +1
Localised tenderness along the distribution of the deep-venous system of the leg +1
Swelling of entire leg +1
Calf swelling at least 3 cm larger than that on the asymptomatic side (measured 10 cm below tibial tuberosity) +1
Pitting oedema confined to the symptomatic leg +1
Collateral superficial veins (non-varicose) +1
Previously documented DVT +1
Alternative diagnosis at least as likely as DVT –2
DVT = deep-vein thrombosis.
*Two-level clinical probability: <2 = unlikely; ≥2 = likely. Three-level clinical probability: ≤0 = low; 1 - 2 = intermediate; ≥3 = high.
Table 5. Wells’ score* for pulmonary embolism 
Criteria Points
Clinical signs and symptoms of DVT +3 
PE is the most likely diagnosis or equally likely v. 
another diagnosis
+3 
Heart rate >100/min +1.5 
Immobilisation for at least 3 days or surgery in the 
previous 4 weeks
+1.5 
Previous, objectively diagnosed PE or DVT +1.5 
Haemoptysis +1 
Malignancy with treatment within 6 months or 
palliation
+1 
DVT = deep-vein thrombosis; PE = pulmonary embolism.
*>6 = high probability; 2 - 6 = moderate probability; <2 = low risk.
187       March 2020, Vol. 110, No. 3
CME
32. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the 
classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4(2):295-306. 
https://doi.org/10.1111/j.1538-7836.2006.01753.x
33. Greinacher A. Heparin-induced thrombocytopenia. N Engl J Med 2015;373(19):1883-1884.
34. Arepally GM. Heparin-induced thrombocytopenia. Blood 2017;129(21):2864-2872. https://doi.
org/10.1056/NEJMc1510993
35. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for 
management of venous thromboembolism: Heparin-induced thrombocytopenia. Blood Adv 
2018;2(22):3360-3392. https://doi.org/10.1182/bloodadvances.2018024489
36. Luzzatto L. Recent advances in the pathogenesis and treatment of paroxysmal nocturnal 
hemoglobinuria. F1000Res 2016;5:pii. https://doi.org/10.12688/f1000research.7288.1
37. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 
2013;121(25):4985-4996,5105. https://doi.org/10.1182/blood-2012-09-311381 
38. Tritschler T, Kraaijpoel N, le Gal G, Wells PS. Venous thromboembolism: Advances in diagnosis and 
treatment. JAMA 2018;320(15):1583-1594. https://doi.org/10.1001/jama.2018.14346
Accepted 31 January 2020.
